Chitosan/Orthobiologics Biomaterials for Regenerative Medicine

点击翻译按钮获取中文摘要

The main goal of the project is to design and create biomaterials to improve treatment of musculoskeletaldisorders, which affect 1.7 billion people globally. The Ortho-R technology, invented at PolytechniqueMontreal, was acquired in 2015 by Ortho Regenerative Technologies Inc (Ortho RTI), and the 2 entities havesince collaborated to pursue its development. A clinical study for the repair of torn tendons has begun in 2022in the United States. R&D work is required to further advance the Ortho-R technology. The company alsowishes to explore new indications for Ortho-R and develop new biomaterials for regenerative medicine. Thetargeted indications are the repair/regeneration of soft tissues (tendon, meniscus, cartilage, ligament), in order to address major medical needs that are largely unmet. The objectives of the project are A) to optimize the manufacturing processes of Ortho-R, B) to elucidate the modes of action and to characterize the structural/mechanical properties of the repair tissues obtained with Ortho-R treatment, C) to assess the potential of Ortho-R for the repair of ligaments and D) to develop new biomaterials with improved properties. This research project will generate new technologies and new intellectual property in the field of regenerative medicine.This project will allow Ortho RTI to continue the development of Ortho-R and to develop new biomaterialsto expand its product portfolio. It will also generate new standardized mechanical tests, in addition to trainingfuture employees of the company Biomomentum. Eventually, new know-how in biomaterial production andanalytical methods will lead to job creation at KABS Laboratories and CERASP. Around 20 highlyspecialized/paid jobs in the promising field of life sciences will be created and highly qualified personnel (>35)will be trained in a professional working/training environment. This large-scale project will make it possible toaddress major medical needs that are largely unmet and will strengthen Canada's leading position in lifesciences while contributing to the country's economic growth.